Jul. 31 at 3:02 PM
$INSM From Barrons;
Insmed, a biopharmaceutical specialist in rare diseases, is stealing the spotlight in 2025 with a stunning 62% gain, especially against the backdrop of XBI's 14% decline.
The daily chart shows a massive 29% gap up on June 10, triggered by positive data on its hypertension drug, followed by a steady climb higher. Now sitting near 25-year highs, Insmed has comfortably held above the very round
$100 number and is trading right at a cup-with-handle pivot at
$105.45.
With momentum on its side, this one looks poised to push toward the
$140 mark by year-end, from its most recent level of
$105.19 Wednesday.
